SLS Europe at Niedersächsischer Life Science Tag 2025
It was a pleasure for Serum Life Science Europe GmbH (SLS Europe) to take part in the Niedersächsischer Life Science Tag 2025 in Hannover today, hosted by Niedersachsen.next / BioRegioN.…
morePress Release: European Commission Grants Marketing Authorisation for SIILTIBCY® – A Novel Tuberculosis Skin Test in Europe
SIILTIBCY® is a tuberculosis skin test approved in European Union that detects tuberculosis infection regardless of BCG vaccination status with demonstrated sensitivity and specificity Full marketing authorisation granted by the…
moreSLS Europe at the TBVI Symposium in Les Diablerets
The SLS Europe team, alongside Serum Institute of India Pvt. Ltd., participated in the TBVI Symposium in Les Diablerets, contributing to discussions on the future of TB vaccine development. Our…
morePress Release: SLS Europe and Bilthoven Biologicals receive positive CHMP Opinion for SIILTIBCY® – a novel Tuberculosis Skin Test in Europe
SIILTIBCY® is poised to be the first skin test in Europe that accurately detects TB, regardless of BCG vaccination status EMA has given a positive recommendation, with a final decision…
moreWrapping Up a Successful SLS Days 2024
We are thrilled to express our gratitude to everyone who participated in the 15th International SLS Days, held on September 12-13, 2024! This year’s event brought together leading experts and…
moreTwo key appointments within our leadership team at SLS Europe
Dr. Fabio Pisano is our new Chief Development Officer. With his extensive experience and invaluable contributions to our company, Fabio will continue to drive innovation and strategic growth of SLS…
moreSLS Europe partners with INCATE to support efforts against antimicrobial resistance
We are pleased to announce a new partnership between Serum Life Science Europe GmbH (SLS Europe) and INCATE (INCubator for Antibacterial Therapies Europe) in the ongoing battle against antimicrobial resistance…
moreReflecting on a successful presence at TBVI Symposium 2024 in Les Diablerets
SLS Europe team, together with Serum Institute of India Pvt. Ltd., presented our leading TB vaccine, VPM1002, contributing to global discussions on TB vaccine innovation. Active engagement and collaboration with…
moreIndia’s TB Battle Explored: BBC News’ Insights on VPM1002
Collaborating with Serum Institute of India Pvt. Ltd., we are proud partners in advancing the groundbreaking TB vaccine candidate, VPM1002. For deeper insights into our efforts, explore BBC’s coverage on…
moreWrapping Up priMe’s Annual Meeting: A Journey Towards Success
With a round of applause and a plethora of insights, Day 2 marks the exciting conclusion of our priMe trial meeting in Entebbe, Uganda. Highlights of Day Two: Collective…
more